Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?
| dc.rights.license | open | en_US |
| dc.contributor.author | KURMA, Keerthi | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation [ImmunoConcept] | |
| dc.contributor.author | BOIZARD MORACCHINI, Andrea | |
| dc.contributor.author | GALLI, Gael | |
| dc.contributor.author | JEAN, Mickael | |
| dc.contributor.author | VACHER, Pierre | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation [ImmunoConcept] | |
| dc.contributor.author | BLANCO, Patrick | |
| dc.contributor.author | LEGEMBRE, Patrick | |
| dc.date.accessioned | 2021-11-05T13:53:24Z | |
| dc.date.available | 2021-11-05T13:53:24Z | |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 0304-419X | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/123764 | |
| dc.description.abstractEn | Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers. We propose to evaluate the various pathologies in which the metalloprotease-cleaved CD95L is accumulated and analyze whether this soluble ligand may play a significant role in the pathology progression. Based on the TNF?-targeting therapeutics, we envision that targeting the soluble form of CD95L may represent a very attractive therapeutic option in the pathologies depicted herein. | |
| dc.language.iso | EN | en_US |
| dc.title.en | Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target? | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.bbcan.2021.188596 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| bordeaux.journal | Biochimica et Biophysica Acta - Reviews on Cancer | en_US |
| bordeaux.volume | 1876 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03333846 | |
| hal.version | 1 | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Biochimica%20et%20Biophysica%20Acta%20-%20Reviews%20on%20Cancer&rft.date=2021&rft.volume=1876&rft.issue=2&rft.eissn=0304-419X&rft.issn=0304-419X&rft.au=KURMA,%20Keerthi&BOIZARD%20MORACCHINI,%20Andrea&GALLI,%20Gael&JEAN,%20Mickael&VACHER,%20Pierre&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||